<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04759391</url>
  </required_header>
  <id_info>
    <org_study_id>2021/02/15</org_study_id>
    <nct_id>NCT04759391</nct_id>
  </id_info>
  <brief_title>Effects of Digital Pelvic Floor Muscle Training in Patients With Multiple Sclerosis Having Lower Urinary Tract Symptoms</brief_title>
  <official_title>Effects of Digital Pelvic Floor Muscle Training and Lifestyle Recommendations in Patients With Multiple Sclerosis Having Lower Urinary Tract Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ataturk Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ataturk Training and Research Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to investigate the effects of digital pelvic floor muscle training&#xD;
      and lifestyle recommendations in patients with Multiple Sclerosis having lower urinary tract&#xD;
      symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple sclerosis (MS) is an autoimmune, neurodegenerative disease of the central nervous&#xD;
      system. Lower urinary tract symptoms (LUTS) are very common in MS. Pelvic floor muscle&#xD;
      training (PFMT) is one of the first-line choices for the conservative treatment of LUTS.&#xD;
&#xD;
      According to our knowledge, no study has investigated the effects of digital pelvic floor&#xD;
      muscle training and lifestyle recommendations in MS having LUTS, yet.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly divided into two groups (control and exercise) for treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incontinence symtoms</measure>
    <time_frame>change from baseline at 8 weeks</time_frame>
    <description>Urinary incontinence symptoms will be evaluated with The International Consultation of Incontinence Questionnaire - Short Form</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overactive bladder symptoms</measure>
    <time_frame>change from baseline at 8 weeks</time_frame>
    <description>Overactive bladder symptoms will be evaluated with Overactive Bladder Questionnaire-Version8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bladder functions</measure>
    <time_frame>change from baseline at 8 weeks</time_frame>
    <description>bladder functions will be evaluated with voiding diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life level</measure>
    <time_frame>change from baseline at 8 weeks</time_frame>
    <description>Quality of life will be evaluated with King's Health Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subjective perception of improvement</measure>
    <time_frame>after treatment (8th week)</time_frame>
    <description>subjective perception of improvement will be evaluated with a 4-item Likert-type scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient satisfaction</measure>
    <time_frame>after treatment (8th week)</time_frame>
    <description>patient satisfaction will be evaluated with a 5-item Likert-type scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lower Urinary Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>Exercise group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lifestyle recommendations as well as digital pelvic floor muscle training to the exercise group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lifestyle recommendations will be given to the control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Pelvic floor muscle training program planned under the supervision of a physiotherapist was applied and followed to the exercise group, using the digital application.</description>
    <arm_group_label>Exercise group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lifestyle recommendations</intervention_name>
    <description>Information was given within the scope of lifestyle recommendations (fluid intake, diet, constipation, weight control, smoking related to lower urinary system symptoms</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Exercise group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having a diagnosis of MS and having at least two of the lower urinary symptoms&#xD;
&#xD;
          -  Not having an attack in the last 1 month,&#xD;
&#xD;
          -  No change in medical treatment in the last 3 months&#xD;
&#xD;
          -  &quot;Expanded disability status scale-EDSS&quot; score is less than 6.5&#xD;
&#xD;
          -  Not having any cognitive problems that would hinder cooperation and understanding&#xD;
&#xD;
          -  Those who use digital devices such as computers, laptops, smartphones and tablets&#xD;
&#xD;
          -  Volunteering to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy status&#xD;
&#xD;
          -  Active urinary tract infection&#xD;
&#xD;
          -  Another neurological disease that can cause incontinence&#xD;
&#xD;
          -  A history of malignancy&#xD;
&#xD;
          -  Prostate surgery&#xD;
&#xD;
          -  Those with missing evaluation parameters&#xD;
&#xD;
          -  Those who do not regularly participate in treatment programs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seyda Toprak Celenay</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ankara Yildirim BeyazÄ±t University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seyda Toprak Celenay</last_name>
    <phone>+90312 906 1000</phone>
    <email>sydtoprak@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ankara Yildirim Beyazit University</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <contact>
      <last_name>Seyda Toprak Celenay</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ataturk Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Seyda TOPRAK CELENAY</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>Lower Urinary Tract Symptoms</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Pelvic Floor Muscle Training</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

